DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
2 hedge funds and large institutions have $0 invested in DMK Pharmaceuticals Corporation Common Stock in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
33% less funds holding
Funds holding: 3 → 2 (-1)
100% less capital invested
Capital invested by funds: $4 → $0 (-$4)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPA
Clear Point Advisors
Melville,
New York
|
-$3 |
DMK Hedge Fund Activity: Q2 2024 in Review
2 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q2 2024, worth a combined $0 — down 100% from $4 a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of DMK and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Clear Point Advisors, exiting entirely with an estimated $3 sold.
- 2 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q2 2024, down from 3 in Q1 2024.
- Funds reported $0 of DMK Pharmaceuticals Corporation Common Stock stock for Q2 2024, down 100% quarter-over-quarter.
- 0 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q2 2024 and 1 closed out, a net change of -1 holder.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q2 2024 was Clear Point Advisors, an estimated $3 sold.
Based on aggregated 13F filings for Q2 2024.